Literature DB >> 11996325

Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.

Alice Laznickova1, M Laznicek, F Trejtnar, L Melicharova, Kazuko Horiuchi Suzuki, Hiromichi Akizawa, Yasushi Arano, Akira Yokoyama.   

Abstract

The present study compares distribution and elimination characteristics of 111In-DTPA-D-Phe1-octreotide and 111In-DTPA-L-Phe1-octreotide in rats and evaluated the effect of the replacement of the terminal L-phenylalanine by D-phenylalanine on pharmacokinetic profiles of the radiolabelled peptides. Both agents exhibited rapid radioactivity clearance from the blood and most organs and tissues with no systematic and significant differences in activity accumulation. The long-term retention and high radioactivity concentrations for both compounds under study were found in the kidneys and organs with a high density of somatostatin receptors, such as the pancreas and adrenals. The residence times in these organs were longer for 111In-DTPA-D-Phe1-octreotide in comparison with 111In-DTPA-L-Phe1-octreotide. The major elimination pathway for both radiolabelled peptides was relatively rapid excretion into the urine. Analysis of the renal handling by an employment of the perfused rat kidney showed that both peptides were eliminated mainly by the mechanism of glomerular filtration. Rat liver perfusion experiments confirmed a very low value of bile clearance of radioactivity for both agents under study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996325     DOI: 10.1007/BF03190403

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  10 in total

Review 1.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

Authors:  S W Lamberts; E P Krenning; J C Reubi
Journal:  Endocr Rev       Date:  1991-11       Impact factor: 19.871

2.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

Review 3.  Studies on radiolabeled somatostatin analogues in rats and in patients.

Authors:  W A Breeman; W H Bakker; M De Jong; L J Hofland; D J Kwekkeboom; P P Kooij; T J Visser; E P Krenning
Journal:  Q J Nucl Med       Date:  1996-09

Review 4.  Radiolabelled peptides: now and the future.

Authors:  M L Thakur
Journal:  Nucl Med Commun       Date:  1995-09       Impact factor: 1.690

Review 5.  Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations.

Authors:  T M Behr; D M Goldenberg; W Becker
Journal:  Eur J Nucl Med       Date:  1998-02

6.  Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.

Authors:  W A Breeman; P M van Hagen; D J Kwekkeboom; T J Visser; E P Krenning
Journal:  Eur J Nucl Med       Date:  1998-02

7.  Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies.

Authors:  P M Smith-Jones; B Stolz; C Bruns; R Albert; H W Reist; R Fridrich; H R Mäcke
Journal:  J Nucl Med       Date:  1994-02       Impact factor: 10.057

8.  Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.

Authors:  H Akizawa; Y Arano; T Uezono; M Ono; Y Fujioka; T Uehara; A Yokoyama; K Akaji; Y Kiso; M Koizumi; H Saji
Journal:  Bioconjug Chem       Date:  1998 Nov-Dec       Impact factor: 4.774

9.  Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals.

Authors:  W H Bakker; E P Krenning; W A Breeman; J W Koper; P P Kooij; J C Reubi; J G Klijn; T J Visser; R Docter; S W Lamberts
Journal:  J Nucl Med       Date:  1990-09       Impact factor: 10.057

10.  Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease.

Authors:  M Láznícek; K E Senius
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.